Skip to main content

Security report for evoxtherapeutics.com

Evox Therapeutics · Healthcare · United Kingdom

Medium risk. 7 critical or high findings in GDPR outside view, SSL/TLS and 1 other check.

Security score

55/100

Risk levelMedium

0–100, higher is better. How it is calculated

Evox Therapeutics is a UK-based biotechnology company specializing in transformative exosome therapeutics targeting severe neurological and neurodegenerative diseases. Leveraging proprietary ExoEdit™ technology and CRISPR/Cas gene editing encapsulated in exosome nanoparticles, Evox aims to develop innovative treatments addressing critical unmet medical needs. The company maintains a professional and content-rich website that clearly communicates its mission, pipeline, technology, and partnership opportunities, targeting patients, healthcare professionals, investors, and collaborators. Technically, the website is built on WordPress using the GeneratePress theme and Elementor page builder, incorporating modern web technologies such as jQuery and Font Awesome. SEO is enhanced via Yoast SEO plugin, and Google Tag Manager is used for analytics and marketing. The site is mobile-optimized with good navigation and accessibility features, although some accessibility and security header improvements are recommended. From a security perspective, the site enforces HTTPS and shows no signs of exposed sensitive data or vulnerable libraries. However, explicit security headers like Content-Security-Policy and X-Frame-Options are not detected, and no formal security or incident response policies are published. Privacy compliance is partially addressed with a comprehensive privacy policy and terms of service, but lacks a cookie consent mechanism. Overall, Evox Therapeutics presents a credible and trustworthy online presence consistent with its business claims and domain registration data. Strategic recommendations include enhancing security headers, implementing cookie consent, publishing security policies, and improving accessibility to strengthen compliance and trust.

Scanned

NIS2 and GDPR posture

GDPR outside view
28/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      No HTTPS encryption

      GDPR requires appropriate security measures for personal data

      What to do: Implement SSL/TLS certificate for HTTPS

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      No HTTPS Encryption

      Website does not use HTTPS encryption, making all data transmission vulnerable to interception

      What to do: Implement SSL/TLS certificate and redirect all HTTP traffic to HTTPS

  3. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

Need hands-on remediation? Email guard@offseq.com

Keep watching evoxtherapeutics.com

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
30
Email security
85
DNS health
85
Network security
100
GDPR outside view
28
Average
55

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Evox Therapeutics occupies a niche in the biotech sector focused on exosome-based gene editing therapies for neurological diseases. Its proprietary technology and active pipeline position it as an innovative player addressing rare and severe conditions. The business model centers on R&D and strategic partnerships, with a clear emphasis on scientific rigor evidenced by publications and press releases. The company targets a specialized audience including medical professionals, investors, and potential collaborators. The website supports business credibility with professional branding, consistent messaging, and active news updates. The presence of LinkedIn and Twitter accounts supports engagement and outreach. No direct revenue streams or e-commerce functionalities are evident, consistent with a biotech R&D company. The company size is medium, founded around 2020, with no parent or subsidiary companies disclosed.

Security posture

The website demonstrates a moderate to good security posture with mandatory HTTPS enabled and no visible exposure of sensitive data. The absence of explicit security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options represents an area for improvement to mitigate risks like clickjacking and MIME sniffing. No vulnerable or outdated libraries were detected in the HTML content. The lack of published security policies or incident response contacts limits transparency and preparedness perception. No forms collecting sensitive data were found on the homepage, reducing immediate attack surface. Privacy compliance is partially addressed but would benefit from cookie consent implementation. Overall, the security posture is adequate for a corporate informational site but could be enhanced to meet higher standards and regulatory expectations.

Recommendations

  1. Implement and enforce security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to improve protection against common web attacks.
  2. Add a cookie consent banner or mechanism to comply with GDPR and other privacy regulations.
  3. Publish a dedicated security policy and incident response contact information to increase transparency and readiness.
  4. Conduct regular security audits of third-party plugins and libraries to ensure no vulnerabilities are introduced.
  5. Enhance website accessibility features to meet WCAG standards and improve user experience for all visitors.

Contact details published on the site

Addresses
Legal name
Evox Therapeutics
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Evox Therapeutics
Description
Evox Therapeutics is committed to transforming the treatment landscape for severe neurological and neurodegenerative diseases by advancing innovative therapeutics through proprietary ExoEdit™ technology to unlock new therapeutic options and positively impact patients and families.
Key services
Development of exosome therapeutics, Proprietary CRISPR/Cas-based gene editing inside exosomes, Strategic partnerships for advancing medicines
Content quality
excellent
Branding
consistent

Technology

Stack
WordPress, Elementor, Yoast SEO, jQuery, Font Awesome, Google Tag Manager
Frameworks
GeneratePress theme, Elementor page builder
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enforced
  • No exposed sensitive data in HTML
  • No visible vulnerable libraries detected

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Transparency
basic

Site quality

Design
excellent
User experience
good
Content relevance
excellent
Navigation
good
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed and content-rich
  2. No signs of blocking or WAF challenges
  3. No visible forms collecting personal data on homepage
  4. Contact information limited to phone and physical address; no email contact found on homepage
  5. Social media presence confirmed via LinkedIn link
  6. No explicit cookie consent mechanism detected
  7. Security headers could be improved
  8. Privacy and terms pages are present and comprehensive
Technical notes

Notes

The website is built on a modern WordPress infrastructure using the GeneratePress theme and Elementor page builder, which provides flexibility and ease of content management. The use of Yoast SEO plugin indicates attention to search engine optimization. Google Tag Manager integration supports marketing and analytics efforts. The site loads a variety of CSS and JS assets including Font Awesome icons and jQuery libraries. Performance is moderate with some large images and multiple CSS/JS files, but overall mobile optimization is good. Accessibility is basic and could be improved. No critical technical debt or deprecated technologies were detected. Hosting provider details are not explicitly disclosed. The site uses structured data (JSON-LD) for SEO and social sharing enhancements. Overall, the technical implementation supports a professional and functional corporate website with room for optimization in performance and security.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with evoxtherapeutics.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review evoxtherapeutics.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.